{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:20:58Z","timestamp":1790241658348,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T00:00:00Z","timestamp":1188259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2007,10,4]]},"DOI":"10.1007\/s00403-007-0784-3","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T16:39:27Z","timestamp":1188232767000},"page":"461-465","source":"Crossref","is-referenced-by-count":52,"title":["Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus"],"prefix":"10.1007","volume":"299","author":[{"given":"Esperanza","family":"Mart\u00ednez-Abundis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Reynoso-von Drateln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Hern\u00e1ndez-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gonz\u00e1lez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,28]]},"reference":[{"key":"784_CR1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/diacare.26.5.1619","volume":"26","author":"Z Bloomgarden","year":"2003","unstructured":"Bloomgarden Z (2003) Inflammation and insulin resistance. Diabetes Care 26:1619\u20131623","journal-title":"Diabetes Care"},{"key":"784_CR2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/diabetes.51.6.1805","volume":"51","author":"S Cottet","year":"2002","unstructured":"Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B (2002) cFLIP Protein prevents tumor necrosis factor-[alpha]-mediated induction of caspase-8-dependent apoptosis in insulin-secreting [beta]Tc-Tet cells. Diabetes 51:1805\u20131814","journal-title":"Diabetes"},{"key":"784_CR3","first-page":"2493","volume":"2","author":"C Culy","year":"2002","unstructured":"Culy C, Keating G (2002) Etanercept. Drugs 2:2493\u20132437","journal-title":"Drugs"},{"key":"784_CR4","first-page":"E214","volume":"6","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo RA, Tobin J, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 6:E214\u2013E223","journal-title":"Am J Physiol"},{"key":"784_CR5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"J Gellfand","year":"2006","unstructured":"Gellfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735\u20131741","journal-title":"JAMA"},{"key":"784_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2001-14949","volume":"33","author":"M Gonz\u00e1lez-Ortiz","year":"2001","unstructured":"Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E, Balc\u00e1zar-Mu\u00f1oz B, Robles-Cervantes J (2001) Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects. Horm Metab Res 33:250\u2013253","journal-title":"Horm Metab Res"},{"key":"784_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000010030","volume":"46","author":"M Gonz\u00e1lez-Ortiz","year":"1998","unstructured":"Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E, Lifshitz A (1998) Insulin sensitivity and sex steroid hormone levels during the menstrual cycle in healthy women with non-insulin-dependent diabetic parents. Gynecol Obstet Invest 46:187\u2013190","journal-title":"Gynecol Obstet Invest"},{"key":"784_CR8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0733-8635(05)70306-5","volume":"19","author":"A Gottlieb","year":"2001","unstructured":"Gottlieb A (2001) Psoriasis: immunopathology and immunomodulation. Dermatol Clin 19:649\u2013655","journal-title":"Dermatol Clin"},{"key":"784_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.7678183","volume":"259","author":"G Hotamisligil","year":"1993","unstructured":"Hotamisligil G, Shargill N, Spiegelman B (1993) Adipose expression of tumor necrosis factor-\u03b1: direct role in obesity-linked insulin resistance. Science 259:7\u201390","journal-title":"Science"},{"key":"784_CR10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.0007-0963.2001.04529.x","volume":"146","author":"S Iyer","year":"2002","unstructured":"Iyer S, Yamauchi P, Lowe N (2002) Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 146:118\u2013121","journal-title":"Br J Dermatol"},{"key":"784_CR11","first-page":"115","volume":"26","author":"L Jeyasseelan","year":"1989","unstructured":"Jeyasseelan L, Rao P (1989) Methods of determining sample sizes in clinical trials. Indian Pediatr 26:115\u2013121","journal-title":"Indian Pediatr"},{"key":"784_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06009.x","volume":"151","author":"T Kormeili","year":"2004","unstructured":"Kormeili T, Lowe N, Yamauchi P (2004) Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies: US experiencies. Br J Dermatol 151:3\u201315","journal-title":"Br J Dermatol"},{"key":"784_CR13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.19126","volume":"34","author":"JM Korth-Bradley","year":"2000","unstructured":"Korth-Bradley JM, Sue-Rubin A, Hanna RK, Simcoe DK, Lebsack ME (2000) The pharmacokinetics of etanercept in healthy volunteer. Ann Pharmacother 34:161\u2013164","journal-title":"Ann Pharmacother"},{"key":"784_CR14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archderm.140.2.218","volume":"140","author":"G Krueger","year":"2004","unstructured":"Krueger G, Callis K (2004) Potential of tumor necrosis factor inhibitor in psoriasis and psoriatic arthritis. Arch Dermatol 140:218\u2013225","journal-title":"Arch Dermatol"},{"key":"784_CR15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0733-8635(05)70304-1","volume":"19","author":"J LaDuca","year":"2001","unstructured":"LaDuca J, Gaspari A (2001) Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 19:617\u2013635","journal-title":"Dermatol Clin"},{"key":"784_CR16","first-page":"2761","volume":"56","author":"R Ludwig","year":"2007","unstructured":"Ludwig R, Herzog C, Rostock A, Ochsendorf F, Zollner T, Thaci D, Kaufmann R, Vogl T, Boehncke W (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 56:2761\u20132627","journal-title":"Br J Dermatol"},{"key":"784_CR17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.ijo.0802187","volume":"27","author":"Y Miyazaki","year":"2003","unstructured":"Miyazaki Y, Pipek R, Mandarino L, DeFronzo R (2003) Tumor necrosis factor \u03b1 and insulin resistance in obese type 2 diabetic patients. Int J Obes 27:88\u201394","journal-title":"Int J Obes"},{"key":"784_CR18","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diab.45.7.881","volume":"45","author":"F Ofei","year":"1996","unstructured":"Ofei F, Hurel S, Newkirk J, Sopwith M Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881\u2013885","journal-title":"Diabetes"},{"key":"784_CR19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1084\/jem.189.7.1053","volume":"189","author":"S Pakala","year":"1999","unstructured":"Pakala S, Chivetta M, Kelly C, Katz J (1999) In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 189:1053\u20131062","journal-title":"J Exp Med"},{"key":"784_CR20","first-page":"1316","volume":"85","author":"N Paquot","year":"2000","unstructured":"Paquot N, Castillo M, Lef\u00e8bvre P, Scheen A (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316\u20131319","journal-title":"J Clin Endocrinol Metab"},{"key":"784_CR21","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1161\/01.CIR.0000091406.72832.11","volume":"108","author":"C Rask-Madsen","year":"2002","unstructured":"Rask-Madsen C, Dom\u00ednguez H, Ihlemann N, Hermann T, K\u00f8ber L, Torp-Pedersen C (2002) Tumor necrosis factor-[alpha] inhibits insulin\u2019s stimulating effect on glucose uptake and endothelium-dependent vasodilatation in humans. Circulation 108:1815\u20131821","journal-title":"Circulation"},{"key":"784_CR22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","volume":"52","author":"K Spranger-Joachim","year":"2003","unstructured":"Spranger-Joachim K, M\u00f6hlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the prospective population-based european prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 52:812\u2013817","journal-title":"Diabetes"},{"key":"784_CR23","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1210\/jcem.85.9.6773","volume":"85","author":"A Eckardstein von","year":"2000","unstructured":"von Eckardstein A, Schulte H, Assmann G (2000) Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 85:3101\u20133108","journal-title":"J Clin Endocrinol Metab"},{"key":"784_CR24","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.2337\/diabetes.50.2007.S154","volume":"50","author":"G Weir","year":"2001","unstructured":"Weir G, Laybutt D, Kaneto H, Bonner-Weir S, Sharma A (2001) Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50:S154\u2013S159","journal-title":"Diabetes"},{"key":"784_CR25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2337\/diacare.22.5.870","volume":"22","author":"G Winkler","year":"1999","unstructured":"Winkler G, Lakatos P, Salamon F, Speer G, Baranyi E, Melczer Z, Karoly C (1999) Response to Fernandez-Real et al. Contribution of tumor necrosis factor-alpha in insulin resistance in patients with android type obesity. Diabetes Care 22:870","journal-title":"Diabetes Care"},{"key":"784_CR26","doi-asserted-by":"crossref","first-page":"A160","DOI":"10.2337\/diabetes.53.1.160","volume":"53","author":"S Yoshitaka","year":"2004","unstructured":"Yoshitaka S, Hiroaki D, Shuji M, Masayuki I, Satoshi T, Tomohiko T, Toshihiko I (2004) Infliximab (anti-tnf alpha antibody) improved insulin resistance in rheumatoid arthritis patients. Diabetes 53:A160\u2013A161","journal-title":"Diabetes"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-007-0784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-007-0784-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-007-0784-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:37:38Z","timestamp":1559065058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-007-0784-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,28]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,10,4]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1007\/s00403-007-0784-3","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,28]]}}}